These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 25569176)
1. Enzalutamide for treatment of CRPC: rationale for sequencing and potential clinical biomarker for resistance. Lochrin SE; Figg WD; Finn SP Cancer Biol Ther; 2015; 16(2):201-3. PubMed ID: 25569176 [TBL] [Abstract][Full Text] [Related]
2. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238 [TBL] [Abstract][Full Text] [Related]
3. [Enzalutamide-a novel androgen receptor inhibitor that provides treatment options for patients with castration-resistant prostate cancer]. Maeda H; Saito A Gan To Kagaku Ryoho; 2014 Jul; 41(7):805-10. PubMed ID: 25131864 [TBL] [Abstract][Full Text] [Related]
4. Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study. Merseburger AS; Attard G; Åström L; Matveev VB; Bracarda S; Esen A; Feyerabend S; Senkus E; López-Brea Piqueras M; Boysen G; Gourgioti G; Martins K; Chowdhury S Lancet Oncol; 2022 Nov; 23(11):1398-1408. PubMed ID: 36265504 [TBL] [Abstract][Full Text] [Related]
5. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study. Conteduca V; Wetterskog D; Sharabiani MTA; Grande E; Fernandez-Perez MP; Jayaram A; Salvi S; Castellano D; Romanel A; Lolli C; Casadio V; Gurioli G; Amadori D; Font A; Vazquez-Estevez S; González Del Alba A; Mellado B; Fernandez-Calvo O; Méndez-Vidal MJ; Climent MA; Duran I; Gallardo E; Rodriguez A; Santander C; Sáez MI; Puente J; Gasi Tandefelt D; Wingate A; Dearnaley D; ; ; Demichelis F; De Giorgi U; Gonzalez-Billalabeitia E; Attard G Ann Oncol; 2017 Jul; 28(7):1508-1516. PubMed ID: 28472366 [TBL] [Abstract][Full Text] [Related]
6. Post hoc analyses of East Asian patients from the randomized placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer. Kim CS; Choi YD; Lee SE; Lee HM; Ueda T; Yonese J; Fukagai T; Chiong E; Lau W; Abhyankar S; Theeuwes A; Tombal B; Beer TM; Kimura G Medicine (Baltimore); 2017 Jul; 96(27):e7223. PubMed ID: 28682871 [TBL] [Abstract][Full Text] [Related]
7. Saracatinib synergizes with enzalutamide to downregulate AR activity in CRPC. White RE; Bannister M; Day A; Bergom HE; Tan VM; Hwang J; Dang Nguyen H; Drake JM Front Oncol; 2023; 13():1210487. PubMed ID: 37456235 [TBL] [Abstract][Full Text] [Related]
8. Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study). Iguchi T; Tamada S; Kato M; Yasuda S; Yamasaki T; Nakatani T BMC Cancer; 2019 Apr; 19(1):339. PubMed ID: 30971225 [TBL] [Abstract][Full Text] [Related]
9. Saracatinib synergizes with enzalutamide to downregulate androgen receptor activity in castration resistant prostate cancer. White RE; Bannister M; Day A; Bergom HE; Tan VM; Hwang J; Nguyen HD; Drake JM bioRxiv; 2023 Apr; ():. PubMed ID: 37163118 [TBL] [Abstract][Full Text] [Related]
10. Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer. Taplin ME; Antonarakis ES; Ferrante KJ; Horgan K; Blumenstein B; Saad F; Luo J; de Bono JS Eur Urol; 2019 Dec; 76(6):843-851. PubMed ID: 31542304 [TBL] [Abstract][Full Text] [Related]
11. Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions. Tucci M; Zichi C; Buttigliero C; Vignani F; Scagliotti GV; Di Maio M Onco Targets Ther; 2018; 11():7353-7368. PubMed ID: 30425524 [TBL] [Abstract][Full Text] [Related]
12. Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer. Golshayan AR; Antonarakis ES Core Evid; 2013; 8():27-35. PubMed ID: 23589709 [TBL] [Abstract][Full Text] [Related]
13. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N; Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502 [TBL] [Abstract][Full Text] [Related]
14. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. Antonarakis ES; Lu C; Wang H; Luber B; Nakazawa M; Roeser JC; Chen Y; Mohammad TA; Chen Y; Fedor HL; Lotan TL; Zheng Q; De Marzo AM; Isaacs JT; Isaacs WB; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J N Engl J Med; 2014 Sep; 371(11):1028-38. PubMed ID: 25184630 [TBL] [Abstract][Full Text] [Related]
15. AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients. Okegawa T; Ninomiya N; Masuda K; Nakamura Y; Tambo M; Nutahara K Prostate; 2018 Jun; 78(8):576-582. PubMed ID: 29508425 [TBL] [Abstract][Full Text] [Related]
16. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201). Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578 [TBL] [Abstract][Full Text] [Related]
17. Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer. Schalken J; Fitzpatrick JM BJU Int; 2016 Feb; 117(2):215-25. PubMed ID: 25818596 [TBL] [Abstract][Full Text] [Related]
18. Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized phase III trial. Izumi K; Mizokami A; Namiki M; Inoue S; Tanaka N; Yoshio Y; Ishibashi K; Kamiyama M; Kawai N; Enokida H; Shima T; Takahara S BMC Cancer; 2017 Oct; 17(1):677. PubMed ID: 29017493 [TBL] [Abstract][Full Text] [Related]
19. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer. van Soest RJ; de Morrée ES; Kweldam CF; de Ridder CMA; Wiemer EAC; Mathijssen RHJ; de Wit R; van Weerden WM Eur Urol; 2015 Jun; 67(6):981-985. PubMed ID: 25484141 [TBL] [Abstract][Full Text] [Related]